Birchview Capital »

Arcus Biosciences Incorporated shares owned by Birchview Capital

Quarter-by-quarter ownership of Arcus Biosciences Incorporated (RCUS) shares owned by Birchview Capital from 13F filings

Historical chart of Birchview Capital investment in Arcus Biosciences Incorporated

Tip: Access up to 7 years of quarterly data

All positions including Arcus Biosciences Incorporated held by Birchview Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Arcus Biosciences Incorporated by Birchview Capital

Quarter filed Position value Share count Share price at filing
2026-03-31 $559k 26k 21.60

More positions owned by Birchview Capital

Kla Corporation Com New (KLAC)
Bristol Myers Squibb (BMY)
Compass Therapeutics (CMPX)
Lam Research Corporation Com New (LRCX)
Stoke Therapeutics (STOK)
Encana Corporation (OVV)
Intellia Therapeutics (NTLA)
Structure Therapeutics Spons Adr (GPCR)
Solid Biosciences Com New (SLDB)
Prothena Corp SHS (PRTA)
Biodesix
ACADIA Pharmaceuticals (ACAD)
Protagonist Therapeutics (PTGX)
Neurocrine Biosciences (NBIX)
Olema Pharmaceuticals (OLMA)

View all positions for Birchview Capital

Top funds holding Arcus Biosciences Incorporated

Gilead Sciences
BlackRock
Vanguard Group
Wellington Management Company
Suvretta Capital Management
State Street Corporation
Vanguard Portfolio Management
Vanguard Capital Management
Woodline Partners
Marshall Wace
Siren
Geode Capital Management
Fisher Investments
Caption Management
Samlyn Capital

View all funds holding Arcus Biosciences Incorporated